November 18, 2026
Leukemia Acute Lymphoblastic Leukemia News

SOHO Insider editors on 2026 highlights in blood cancers

As 2026 comes to a close, the SOHO Insider editors reflect on this year’s news in blood cancers.

Elias Jabbour, MD, University of Texas MD Anderson Cancer Center

Newly diagnosed ALL is moving toward chemotherapy-free regimens or regimens with less chemotherapy. Early integration of CAR T-cell therapy in ALL may further improve outcomes and spare patients the need for allogeneic stem cell transplantation.

Tom Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center

The myeloma treatment landscape continues to evolve, and several clinical trial results reported within the past 12 months are changing the way in which we approach and treat early relapsed multiple myeloma. Novel immunotherapies, like CAR T-cell therapies and BCMA-targeted bispecific antibodies, initially showed promise in late relapse (ie, in patients who had experienced multiple relapses and received more than three prior lines of therapy). However, the latest data have tested these therapeutics and additional novel agents in patients with early relapse disease (one to three prior lines of therapy), showing even more dramatic results.

One of the most impressive results was reported from the MajesTEC-3 study, in which patients were randomly assigned to either the combination of daratumumab (Dara) and teclistamab (Tec) or a standard triplet of daratumumab, pomalidomide and dexamethasone (DPd) or daratumumab, bortezomib and dexamethasone (DVd). Tec-Dara decreased the risk of progression or death by more than 80%, and the 36-month progression-free survival rate was 83%, a new benchmark for myeloma therapeutics.

Several additional phase 3 studies have been reported, including single-agent teclistamab vs. DPd or DVd; talquetamab + Dara or talquetamab + Dara + Pom vs. DPd/DVd; and the novel CELMoD iberdomide + daratumumab + dexamethasone (Iber-Dara-dex) versus daratumumab + bortezomib + dexamethasone. In all studies, there were significant improvements in depth of response and PFS in the experimental arms.

Thus, when a patient has early relapse, I offer CAR T-cell therapy if they are a candidate, as the first option, but also have a detailed discussion about Tec-Dara, Iber-Dara-dex, Tal-Dara-dex and the art of sequencing. The early relapse MM discussion is now the longest discussion and one of the most important.

For the first time ever, it is possible that a significant number of patients may never experience a subsequent relapse after “salvage” therapy and that their second remission duration will be longer than their remission after frontline therapy.

Still more trials will be presented in 2026 and 2027, and it is truly an amazing time to be treating patients with MM.

Susan O’Brien, MD, University of California, Irvine School of Medicine

Pirtobrutinib, the only FDA-approved noncovalent BTK inhibitor for patients who have progressed on a covalent BTK inhibitor, has now also received frontline approval in CLL. It will be interesting to see how much first-line use it gets, because everyone knows it works after progression on a covalent BTK inhibitor, but we don’t know whether the reverse sequence would also work.

At EHA in June 2026, a randomized trial comparing pirtobrutinib, venetoclax, and rituximab (PirtoVenR) with venetoclax and rituximab (VenR), a standard regimen in relapsed disease, showed that PirtoVenR produced better PFS. This will likely lead to FDA approval of this triplet for relapsed CLL by next year.

Acalabrutinib plus venetoclax received FDA approval as the first all-oral, fixed-duration regimen for CLL in the US. Ibrutinib plus venetoclax is approved in more than 50 countries outside the US, but not in the US. Until now, the only approved fixed-duration regimen was venetoclax-obinutuzumab (VenO), and obinutuzumab is a monoclonal antibody that must be given intravenously.

The final analysis of the CLL14 trial, which led to the approval of VenO, was also presented at EHA. With a median follow-up of more than 9 years, it showed a median PFS of 76.6 months, a median time to next treatment of just over 7.5 years, and a median OS not yet reached, all with only 1 year of fixed-duration therapy.

Finally, BTK degraders from both Nurix and BeOne are producing exciting efficacy results with an excellent safety profile in heavily pretreated patients with CLL. No degraders are FDA approved in CLL yet.

Jerald Radich, MD, Fred Hutchinson Cancer Center

CML: For wealthy countries, the long-term data on asciminib confirm excellent efficacy and better tolerability than other TKIs. For the rest of the world, the Max Foundation’s demonstration that treatment-free remission is possible in low-resource settings could be a worldwide game changer.

Leave feedback about this

  • Quality
  • Price
  • Service

PROS

+
Add Field

CONS

+
Add Field